- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02152306
Fimasartan/Amlodipine Combination Phase III
July 24, 2015 updated by: Boryung Pharmaceutical Co., Ltd
A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.
The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan 60mg monotherapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
143
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi
-
Bundang, Gyeonggi, Korea, Republic of, 463-707
- Seoul National University Bundang Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who voluntarily signed informed consent for participating in this clinical trial
- Male and Female between 20 and 75 years old
- Patients with essential hypertension
- Patients who is unresponsive to Fimasartan 60mg monotherapy for 4 weeks (i.e. the mean SiDBP from 3 times of measurement is 140mmHg ≤ SiSBP <180 mmHg)
- Understand the trial procedures and be willing to cooperate and complete the trial.
Exclusion Criteria:
- Severe Hypertension patients (SiDBP ≥ 110mmHg and/or SiSBP ≥ 180mmHg)
- Subjects with the difference between blood pressures from a selected arm, SiDBP ≥10 mmHg or SiSBP ≥20 mmHg, at screening assessment
- Secondary hypertension patients, but not limited to the following disease;(example: renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromo-cytoma, polycystic kidney disease, etc.)
- Clinically significant renal function abnormality in the laboratory results at screening (i.e. serum creatine ≥ 1.5 times upper normal limit (UNL)), liver function abnormality (ALT, AST ≥ 2 times upper normal limit (UNL)), severe fatty liver disease that requires medication
- Clinically significant Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded 5.5mmol/L)
- Subjects with following surgical and internal disease that may affect absorption, distribution, metabolism or excretion of drugs and have conditions which include the following (but are not limited to): history of major gastrointestinal surgeries including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass graft and stapling; current active gastritis, ulcer, gastrointestinal and rectal bleeding, presence of active inflammatory bowel syndrome within the past 12 months; or clinically significant urinary obstruction at discretion of investigator
- Subjects with depletion of body fluid or sodium ion not able to correct
- Subjects with severe insulin-dependent Diabetes Mellitus (DM) or chronic DM (HbA1c>9%, dosage of an oral hypoglycemic agent was modified within the past 12 weeks, or use of active insulin treatment at screening)
- Subjects with severe heart disease (heart failure New York Heart Association(NYHA) Class III and IV), or history of any of the followings within the past 6 months; ischemic heart disease(e.g. angina pectoris, myocardial infarction), peripheral vascular disease, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft.
- Subjects with clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or any other clinical significant arrhythmia conditions at discretion of investigator.
- Subjects with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or mitral valve stenosis.
- Subjects with severe cerebrovascular disorder (e.g. stroke, cerebral infarction or cerebral hemorrhage within the past 6 months).
- Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory therapy, Past or current medical history with wasting disease, autoimmune diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus ) or connective tissue disease.
- Subjects with known moderate or malignant retinosis (e.g. retinal hemorrhage, visual disturbance or retinal microaneurysm in the past 6 months).
- Subjects with hepatitis B (including positive test for HBsAg), hepatitis C-positive.
- Subjects with history or evidence of abusing drugs or alcohol within the past 2 years.
- Medical history with hypersensitivity to angiotensin II antagonist-based drugs or calcium-channel blockers
- Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Pregnant women and lactating female
- Women of childbearing potential who are not using effective contraceptive methods. (Excluding subjects who had surgically sterilized. All women of childbearing potential who did not have surgical sterilization must prove negative in a pregnancy test, and continue to use accepted and effective contraceptive methods until the end of the study in order to participate. Not accepted contraceptive method: Periodic abstinence and celibacy (e.g. Basic body temperature method, menstrual cycle calculation), hormonal contraceptives.
- Subject who is participating in another trial or took other investigational product within12 weeks from the screening visit
- Medical history of all kinds of malignant tumor including leukemia and lymphoma in the past 5 years
- A subject with other reasons not specified above that, ineligible to participate in this clinical trial at discretion of study investigators.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fimasartan and Amlodipine
Combination of Fimasartan and Amlodipine
|
|
Active Comparator: Fimasartan
Fimasartan Monotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline
Time Frame: 8 weeks from Baseline Visit
|
To compare the difference of Mean Systolic Blood Pressure at 8 weeks from baseline visit
|
8 weeks from Baseline Visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline
Time Frame: 4 weeks from Baseline Visit
|
4 weeks from Baseline Visit
|
Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline
Time Frame: 4 and 8 weeks from Baseline Visit
|
4 and 8 weeks from Baseline Visit
|
Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration
Time Frame: 8 weeks from Baseline Visit
|
8 weeks from Baseline Visit
|
The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration
Time Frame: 8 weeks from Baseline Visit
|
8 weeks from Baseline Visit
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events
Time Frame: 12 weeks from Screening Visit
|
12 weeks from Screening Visit
|
Adverse Changes in Laboratory Test Results
Time Frame: 12 weeks from Screening Visit
|
12 weeks from Screening Visit
|
Adverse Changes in Electrocardiography (ECG)
Time Frame: 12 weeks from Screening Visit
|
12 weeks from Screening Visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Cheol Ho Kim, Ph.D., Seoul National University Bundang Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
March 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
May 29, 2014
First Submitted That Met QC Criteria
May 29, 2014
First Posted (Estimate)
June 2, 2014
Study Record Updates
Last Update Posted (Estimate)
July 27, 2015
Last Update Submitted That Met QC Criteria
July 24, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Essential Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Amlodipine
Other Study ID Numbers
- BR-FAC-CT-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Hypertension
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on Fimasartan and Amlodipine
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdKyunghee university hospital A Drug Analytical LaboratoryCompleted
-
Boryung Pharmaceutical Co., LtdCompletedDyslipidemia | Essential HypertensionKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompletedHypertension | HyperlipidemiaKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University Hospital; Kyungpook National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdYonsei University; Kyungpook National University HospitalCompletedEssential Hypertension | Hepatic ImpairmentKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompleted